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Introduction:  While  nicotine  replacement  therapy  (NRT)  is  an  effective  pharmacological  smoking  ces-
sation  treatment,  its efﬁcacy  is  inﬂuenced  by  adherence  to and  consumption  of the  prescribed  dose.
The  genetic  variant  rs1051730  in  the  nicotinic  receptor  gene  cluster  CHRNA5-A3-B4  inﬂuences  smoking
quantity.  The  aim  of  this study  was  to explore  the  impact  of  rs1051730  genotype  on  adherence  to  and
consumption  of  NRT  prescription  following  a  smoking  cessation  attempt.
Methods:  Secondary  analysis  of  data  from  a  pharmacogenetic  smoking  cessation  trial. Participants
(n  =  448)  were  prescribed  a daily  dose  of  NRT for  four  weeks  post  quit  attempt,  and monitored  dur-
ing  weekly  clinic  visits.  Outcome  measures  were  NRT  prescription  adherence  rate  (%) and  average  daily
NRT  consumption  (mg)  at 7- and  28-days  after  the  quit attempt.
Results:  An  association  between  rs1051730  genotype  and  both  outcome  measures  was  observed  at 7-
days  after  the quit date.  Each  copy  of the  minor  allele  corresponded  to a 2.9%  decrease  in adherence  to
prescribed  NRT  dose  (P = 0.044),  and a  1.0 mg  decrease  in  daily NRT  consumption  (P  = 0.026).  Adjusting
for  number  of  cigarettes  smoked  during  this  period  only  slightly  attenuated  these  associations.  There
was  no clear  statistical  evidence  of an  association  between  genotype  and  adherence  or consumption  at
28-days.
Conclusions:  This  is  the  ﬁrst  study  to evaluate  the  impact  of  rs1051730  genotype  on  consumption  of
and  adherence  to NRT  prescription  during  a smoking  cessation  attempt.  We  observed  an  association
between  this  variant  and  both  outcome  measures  at 7-days;  however,  this  was  only  moderate.  These
ﬁndings  require  replication  in  an  independent  sample.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY. Introduction
Nicotine replacement therapy (NRT) is an effective pharmaco-
ogical smoking cessation treatment relative to placebo (Cahill et al.,
013). The efﬁcacy of NRT is inﬂuenced by a number of factors,
ncluding type of NRT used, and combination versus single type
se (Cahill et al., 2013). Adherence to and consumption of NRT
∗ Corresponding author at: School of Social and Community Medicine, Oakﬁeld
ouse, Oakﬁeld Grove, Bristol BS8 2BN, United Kingdom. Tel.: +44 117 9288547.
E-mail address: jen.ware@bristol.ac.uk (J.J. Ware).
ttp://dx.doi.org/10.1016/j.drugalcdep.2015.03.035
376-8716/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access license  (http://creativecommons.org/licenses/by/4.0/).
prescription also inﬂuences efﬁcacy; Shiffman (2007) showed that
the use of more NRT lozenges was associated with better smoking
cessation outcomes—each additional lozenge consumed was asso-
ciated with increased odds of quitting success by 10%. Maximising
treatment adherence and consumption is likely to maximise treat-
ment efﬁcacy, and identifying factors that inﬂuence this may
therefore be valuable.
Several factors underlie differences in adherence to and con-
sumption of NRT, such as the form in which it is prescribed (Hajek
et al., 1999; Hollands et al., 2013). Genetic factors may  also inﬂuence
adherence to and consumption of NRT. One genetic locus rele-
vant to smoking behaviours lies within the nicotinic acetylcholine
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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eceptor subunit gene cluster CHRNA5-A3-B4 on chromosome 15.
ariants rs1051730 in CHRNA3 and rs16969968 in CHRNA5 (which
re almost perfectly correlated in European populations and there-
ore essentially interchangeable) robustly associate with nicotine
ependence, self-reported and objective assessments of smoking
uantity (e.g., cotinine levels), and several smoking-related dis-
ases, the minor allele conferring increased risk (Munafo et al.,
012; Thorgeirsson et al., 2008; Ware et al., 2012). Notably,
s16969968 is a missense mutation, resulting in an amino acid
hange (aspartate to asparagine) in the resultant alpha-5 nicotinic
eceptor subunit protein. This change is associated with reduced
eceptor function in vitro (Bierut et al., 2008). Preclinical evidence
uggests that that the alpha-5 nicotinic receptor subunit, encoded
y CHRNA5, inﬂuences self-titrated nicotine exposure via tolerance
o the toxic effects of high doses of nicotine (Fowler et al., 2011).
here is also evidence that this variant is associated with a reduced
ikelihood of smoking cessation (Munafo et al., 2011; Taylor et al.,
014), and reduced body mass index (BMI) in individuals who
moke (Freathy et al., 2011).
Identifying genetic variants associated with adherence to and
onsumption of NRT would be valuable for a number of rea-
ons. First, it may  provide insight into individual differences in
he use of NRT, and inform treatment strategies. Second, it might
fford genetic variants suitable for use as instrumental variables in
endelian randomisation analyses of large, existing datasets (Ware
nd Munafo, 2014). This latter approach, in particular, would enable
he efﬁcient exploration of the consequences of adherence and
onsumption on a range of outcomes. Therefore, using data from
 smoking cessation trial, we explored the impact of rs1051730
enotype on adherence to and consumption of an NRT prescription
ollowing a smoking cessation attempt.
. Materials and methods
.1. Design and overview
We  conducted a secondary analysis of data from a randomised
ontrolled trial investigating the impact of informing smokers that
heir prescribed NRT dose had been tailored according to geno-
ype (OPRM1) or phenotype (nicotine dependence). Full details
f this trial have been reported previously (Marteau et al., 2012,
010). Ethics approval for this trial was granted by the Hertford-
hire Research Ethics Committee (06/Q0201/21). Informed written
onsent was obtained from all study participants.
.2. Participants
Participants were adult smokers who had consumed at least 10
igarettes per day over the preceding 12 months, and were moti-
ated to quit. Cigar, pipe and oral tobacco users who did not also
moke 10 or more cigarettes per day were excluded. Additional
xclusion criteria included contraindication for NRT use, previous
evere adverse reactions to NRT patch or oral NRT, current use
f smoking cessation medication, and current use of medication
or another indication with a known inﬂuence on smoking cessa-
ion (e.g., nortriptyline). Non-English speakers and those deemed
nsuitable for the study by their primary care physicians were also
xcluded. The trial took place in smoking cessation clinics in pri-
ary care.
.3. ProcedureAll participants were offered behavioural support and an NRT
rescription. Behavioural support was offered twice prior to quit
ay and weekly thereafter for four weeks. An additional sessionendence 151 (2015) 236–240 237
was offered eight weeks after the quit date. NRT consisted of a nico-
tine patch, the strength of which was based on the participant’s
daily cigarette consumption (10–14 cigarettes per day = 14 mg;
≥15 cigarettes per day = 21 mg). In addition, participants were also
prescribed a second, oral ‘top-up’ form of NRT (gum, lozenge, sub-
lingual tablet or inhalator), which delivered 6 or 12 mg of absorbed
nicotine. This ‘top-up’ dosage was based on OPRM1 genotype or
level of nicotine dependence (determined by the Fagerström Test
for Nicotine Dependence; Heatherton et al., 1991) depending on
which treatment arm of the trial the participant had been ran-
domised to. NRT was prescribed for four weeks from the quit date.
Participants attended seven weekly clinic sessions. Baseline
measures were assessed during the ﬁrst clinic session. NRT was
prescribed and a quit date agreed during the second session. The
quit attempt commenced after the third session. Participants were
requested to take their NRT as prescribed for four weeks post quit
attempt and to attend weekly clinic sessions, where NRT adherence
checks were performed and repeat prescriptions administered.
Information regarding use of cigarettes during the preceding week
was also collected during clinic sessions.
2.4. Genotyping
DNA was extracted from EDTA-venous blood samples and
Picogreen quantiﬁed (Invitrogen). Genotyping of rs1051730 was
conducted by competitive allele-speciﬁc PCR KASPar chemistry
(LGC, Hertfordshire, UK) implemented on an ABI7900HT plat-
form (Applied Biosystems, Foster City, USA) (details available on
request).
2.5. Outcome measures
Adherence to prescription of NRT: Adherence was  deﬁned as the
proportion (%) of all NRT prescribed that was consumed on each
day, averaged over 7 and 28 days after the quit date, and was
assessed by the clinic nurse during weekly clinic visits. Assessments
were based on participant diaries and a count of remaining NRT.
Daily NRT consumption: Consumption was deﬁned as the dose of
nicotine consumed on each day (mg), averaged over 7 and 28 days
after the quit date, calculated using total prescribed daily dose (i.e.,
20, 26, 27 or 33 mg)  and relevant adherence rate.
2.6. Statistical plan
Linear regression was  used to assess the relationship between
rs1051730 genotype and NRT adherence and consumption out-
comes. Genotype was coded additively according to the number of
minor alleles (0, 1, 2) and treated as a continuous variable. Unad-
justed, partially adjusted, and fully adjusted models were tested for
each outcome at 7- and 28-day time points. The partially adjusted
model adjusted for age, sex, socioeconomic position, trial condi-
tion (i.e., genotype or phenotype arm), baseline BMI  and baseline
daily cigarette consumption. The fully adjusted model additionally
adjusted for number of cigarettes smoked on top of NRT prescrip-
tion during the speciﬁed period.
Given the previously observed association between rs1051730
and short-term smoking cessation success (Munafo et al., 2011),
where we observed an association between genotype and NRT
adherence and consumption outcomes, we re-ran these analyses
limiting our sample to those individuals who were abstinent. This
was done so as to rule out smoking relapse as a potential explana-
tion for any association observed between genotype and outcome
measures. At the 7-day time point, abstainers were deﬁned as those
reporting smoking fewer than 5 cigarettes in the ﬁrst week after
the quit date (n = 315), while at the 28-day time point abstain-
ers were deﬁned using Russell standard procedures (West et al.,
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005) as those reporting smoking fewer than 5 cigarettes in the
ast two weeks, veriﬁed by an exhaled carbon monoxide reading
f less than 10 ppm, and counting participants lost to follow up as
eing smokers (n = 245).
With the sample available for analysis (n = 448), assuming a
inor allele frequency of 0.35 and an additive model of inheritance,
e calculated that we had 80% power to detect a 4.1% (7 days) and
.8% (28 days) reduction in NRT adherence per minor allele, and a
.3 mg  (7 days) and 1.7 mg  (28 days) reduction in NRT consumption
er minor allele at an alpha level of 5%. We  also examined the rela-
ionship between rs1051730 genotype and smoking abstinence at
 and 28 days (as deﬁned above) using logistic regression. A 2 test
as used to assess whether genotype frequencies deviated from
ardy-Weinberg equilibrium. All analyses were conducted in SPSS
ersion 21 (IBM Corp., Armonk, NY).
. Results
.1. Participant selection
Of the 633 individuals who were randomised in the full trial, we
imited our analyses to those of European ancestry with rs1051730
ata and NRT prescription adherence rates >0% at 7 days. This
esulted in a ﬁnal sample size of 448.
.2. Participant demographicsParticipant demographic information and baseline measures are
resented for the full sample and by rs1051730 genotype in Table 1.
enotype frequencies for rs1051730 did not deviate substantially
rom Hardy-Weinberg equilibrium (P = 0.06).
able 1
emographic characteristics and baseline measures.
Total sample rs1051730 genot
GG 
Total sample (N, %) 448 (100%) 201 (43.0%)
Age  (M,  SD) 48.2 (12.9) 49.8 (12.6) 
FTND  (M,  SD) 5.6 (2.2) 5.7 (2.1) 
Cigarettes/Day (M,  SD) 21.1 (8.5) 21.2 (8.1) 
Sex  (N, %)
Male 205 (45.8%) 84 (41.8%) 
Female 243 (54.2%) 117 (58.2%) 
BMI  (M,  SD) 27.2 (5.6) 27.1 (5.4) 
SES  (N, %)
Low 130 (29.0%) 65 (32.3%) 
Medium 156 (34.8%) 57 (28.4%) 
High  162 (36.2%) 79 (39.3%) 
Trial  condition (N, %)
Genotype 226 (50.4%) 102 (50.7%) 
Phenotype 222 (49.6%) 99 (49.3%) 
NRT  Prescription (N, %)
20 mg  76 (17.0%) 29 (14.4%) 
26  mg 7 (1.6%) 4 (2.0%) 
27  mg 281 (62.7%) 130 (64.7%) 
33  mg 84 (18.8%) 38 (18.9%) 
-values generated using chi-square test for categorical variables and one-way ANOVAs fo
ES  = socioeconomic status; FTND = Fagerström test for nicotine dependence; NRT = nicot
xception of BMI  which was  based on total sample of 435 (11 individuals with missing daendence 151 (2015) 236–240
3.3. Impact of rs1051730 on adherence to NRT prescription
An association between rs1051730 genotype and adherence to
NRT prescription was  observed at 7 days after the quit attempt
(see Table 2). Each copy of the minor allele corresponded to a 2.9%
decrease in adherence to prescribed NRT dose over this time period
(95% CI −5.6% to −0.1%, P = 0.044). This association was robust to
adjustments made for age, sex, socioeconomic status, trial condi-
tion, baseline BMI  and baseline daily cigarette consumption (−3.0%,
95% CI −5.8% to −0.1%, P = 0.043). Additionally adjusting for num-
ber of cigarettes smoked in addition to NRT during this period only
slightly attenuated this association (−2.4%, 95% CI −4.9% to 0.1%,
P = 0.061). Limiting the sample to those individuals who  reported
smoking fewer than 5 cigarettes in the ﬁrst week had little impact
on this association (unadjusted [n = 315]: −3.0%, 95% CI −5.5% to
−0.5%, P = 0.021; partially adjusted [n = 306]: −3.0%, 95% CI −5.6%
to −0.3%, P = 0.027; fully adjusted [n = 306]: −3.0%, 95% CI −5.6%
to −0.4%, P = 0.026). No association between genotype and adher-
ence was  observed at 28-days after the quit attempt (Ps > 0.61 for
unadjusted, partially adjusted and fully adjusted analyses).
3.4. Impact of rs1051730 on NRT consumption
An association between rs1051730 genotype and average daily
NRT consumption was  observed at 7 days after the quit attempt
(see Table 2). Each copy of the minor allele corresponded to a
1.0 mg  decrease in mean daily NRT consumption over this time
period (95% CIs −1.8 mg  to −0.1 mg,  P = 0.026) (for reference, mean
daily NRT consumption for the full sample within this time period
was 22.9 mg). This association was robust to adjustments made for
age, sex, socioeconomic status, trial condition, baseline BMI  and
baseline daily cigarette consumption (−1.0 mg,  95% CIs −1.9 mg to
−0.2 mg,  P = 0.021). Additionally adjusting for number of cigarettes
smoked on top of NRT during this period had little impact this
ype
GA AA P-value
184 (39.4%) 63 (13.5%) N/A
47.5 (13.1) 45.3 (12.7) 0.031
5.5 (2.3) 5.6 (2.1) 0.497
20.9 (8.7) 21.5 (9.5) 0.873
90 (48.9%) 31 (49.2%) 0.314
94 (51.1%) 32 (50.8%)
27.5 (6.1) 26.3 (4.8) 0.336
49 (26.6%) 16 (25.4%) 0.035
68 (37.0%) 31 (49.2%)
67 (36.4%) 16 (25.4%)
90 (48.9%) 34 (54.0%) 0.782
94 (51.1%) 29 (46.0%)
37 (20.1%) 10 (15.9%) 0.518
3 (1.6%) 0 (0.0%)
107 (58.2%) 44 (69.8%)
37 (20.1%) 9 (14.3%)
r continuous variables. M = mean; SD = standard deviation; BMI = body mass index;
ine replacement therapy. All analyses based on sample of 448 individuals with the
ta, 2 individuals with severely outlying BMI  values [>100]).
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Table  2
The impact of rs1051730 genotype on adherence to prescribed NRT dose and actual NRT consumption following a quit attempt.
Outcome Unadjusted Partially adjusted Fully adjusted
N B (95% CI) P-value N B (95% CI) P-value N B (95% CI) P-value
7 days
Adherence 448 −2.856 (−5.631 to −0.082) 0.044 435 −2.967 (−5.844 to −0.090) 0.043 413 −2.372 (−4.853 to 0.108) 0.061
Consumption 448 −0.970 (−1.823 to −0.116) 0.026 435 −1.003 (−1.851 to −0.155) 0.021 413 −0.865 (−1.606 to −0.124) 0.022
28  days
Adherence 448 −0.990 (−4.882 to 2.902) 0.617 435 −0.680 (−4.669 to 3.309) 0.738 294 0.150 (−2.045 to 2.344) 0.893
Consumption 448 −0.522 (−1.648 to 0.603) 0.362 435 −0.427 (−1.574 to 0.720) 0.465 294 −0.151 (−0.895 to 0.593) 0.690
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osition, trial condition (i.e., top-up prescription based on genotype or phenotype
djusts  for number of cigarettes smoked on top of NRT prescription during the spec
ffect (−0.9 mg,  95% CIs −1.6 mg  to −0.1 mg,  P = 0.022). A sim-
lar association was observed when the sample was limited to
hose individuals who reported smoking fewer than 5 cigarettes
n the ﬁrst week (unadjusted [n = 315]: −1.0 mg,  95% CIs −1.9 mg
o −0.2 mg,  P = 0.020; partially adjusted [n = 306]: −0.9 mg,  95% CIs
1.7 mg  to 0.0 mg,  P = 0.039; fully adjusted [n = 306]: −0.9 mg,  95%
Is −1.7 mg  to 0.0 mg,  P = 0.039). No association between geno-
ype and NRT consumption was observed at 28 days (Ps > 0.36 for
nadjusted, partially adjusted and fully adjusted analyses).
.5. Impact of rs1051730 on abstinence
There was  no evidence of association between rs1051730 and
ikelihood of abstinence at 7 days (OR = 1.10, 95% CIs 0.81 to 1.51,
 = 0.55) or 28 days (OR = 0.89, 95% CIs 0.68 to 1.16, P = 0.39). These
esults were not altered substantially when adjusted for age, sex,
ocioeconomic position, trial condition, baseline BMI  and baseline
aily cigarette consumption.
. Discussion
To our knowledge this is the ﬁrst study to explore the associa-
ion of rs1051730 genotype on consumption of and adherence to
RT prescription during a smoking cessation attempt. We  observed
n association with both outcome measures at 7 days after the quit
ttempt, each copy of the minor allele conferring a 2.9% decrease in
dherence to prescribed NRT dose, and a 1.0 mg  decrease in average
aily NRT consumption. However, no clear evidence of association
f rs1051730 with either outcome was observed at 28 days. Under-
tanding the factors that underlie adherence to and consumption of
RT is of clinical importance given the likely impact of actual NRT
onsumption on smoking cessation outcomes. Using data from the
ame trial, Hollands et al. (2013) found that the odds of 28 day absti-
ence increased by 5% for each additional 1 mg  of NRT consumed
er day.
Previous research has demonstrated a robust association
etween rs1051730 and measures of smoking quantity, both self-
eported and objective; the minor allele is associated with higher
ndices of smoking quantity. Given this, one might hypothesise that
he minor allele would be associated with increased adherence
o and consumption of prescribed NRT, in an effort to achieve an
dequate nicotine dose to alleviate withdrawal. However, the asso-
iation observed between genotype and adherence/consumption
utcomes at 7 days was in the opposite direction. Moreover, the
ssociation observed was only mildly attenuated by adjustment for
aseline daily cigarette consumption and cigarettes smoked on top
f NRT prescription during the speciﬁed period. It is worth noting
hat any association of genotype with adherence/consumption may
e mediated via tolerance to nicotine. If so, adjustment for cigarette
onsumption may  in fact lead to adjustment for this mediating
echanism. The fact that this adjustment did not alter our results of the rs1051730 A allele. Partially adjusted model includes age, sex, socioeconomic
line daily cigarette consumption, and baseline BMI. Fully adjusted model further
eriod.
substantially indicates that nicotine tolerance may  not in fact be the
relevant mediating mechanism. However, given the known plastic-
ity of smoking behaviour this adjustment is likely to be imperfect
(McNeill and Munafo, 2013; Munafo et al., 2012), which precludes
drawing strong conclusions from the relatively little change that
this adjustment made to our results.
One potential explanation for the effect we  observed is that
rs1051730 minor allele carriers were more likely to abandon their
quit attempt and treatment prior to the end of the trial. This is cer-
tainly plausible; the rs1051730 minor allele was associated with
reduced likelihood of cessation success at 4 weeks in open-label
NRT study (Munafo et al., 2011). If minor allele carriers were aban-
doning their quit attempt and hence treatment during the 7-day
period, this would result in an association between rs1051730
genotype and NRT adherence/consumption; that is, the minor allele
would be associated with reduced adherence and consumption, as
we observed. To explore this issue, we  re-ran the 7-day analyses
limiting the sample to those individuals who  reported smoking
fewer than 5 cigarettes in the ﬁrst week post quit. However, we
observed the same association in this sub-sample, which is incon-
sistent with this explanation. Further, no association was observed
between rs1051730 and smoking abstinence at either time-point,
but this may  have been due to lack of statistical power, and the
odds ratio at 28 days was  comparable to previously observations
(Munafo et al., 2011).
Two  study limitations are worthy of note. First, consumption
of and adherence to NRT prescription were determined from par-
ticipant diaries and counts of remaining medication during clinic
sessions. Cotinine levels would have provided a more precise,
objective assessment of these outcomes. Second, our sample was
small for a genetic association study, and a replication sample
was not available. These ﬁndings should therefore be considered
preliminary and hypothesis-generating until replicated indepen-
dently.
Using data from a smoking cessation trial, we  observed an
association between rs1051730 genotype and adherence to and
consumption of NRT prescription. Each copy of the minor allele was
associated with decreased consumption and adherence at 7 days
after the quit attempt, although no association of genotype and con-
sumption or adherence was observed at 28 days. However, given
the weak statistical evidence for association, our ﬁndings should be
interpreted with caution, and replication in an independent sample
sought.
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